Sanofi (SNY) Shares Outstanding (2009 - 2026)
Sanofi (SNY) posted Shares Outstanding (Entity) of $1.2 billion for Q2 2026, up 0.82% sequentially from $1.2 billion in Q1 2026, and down 1.11% YoY from $1.2 billion in Q2 2025.
Sanofi (SNY) Shares Outstanding (2009 - 2026) Analysis & Trends
Sanofi has reported Shares Outstanding (Entity) for 18 years, with the latest figure at $1.2 billion in Q2 2026.
- Quarterly Shares Outstanding (Entity) fell 1.11% year-over-year to $1.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.2 billion (down 1.11% YoY) and the FY2025 annual result came in at $1.2 billion, down 3.46% from the prior year.
- Shares Outstanding (Entity) advanced to $1.2 billion in Q2 2026 per SNY's latest filing, from $1.2 billion in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $1.3 billion in Q2 2024 and troughed at $1.2 billion in Q1 2026.
- A 5-year average of $1.2 billion and a median of $1.3 billion in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) grew 0.37% in 2022, then slipped 3.46% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $1.3 billion in 2022, then gained by 0.31% to $1.3 billion in 2023, then slipped by 0.13% to $1.3 billion in 2024, then dropped by 3.46% to $1.2 billion in 2025, then dropped by 0.44% to $1.2 billion in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.2 billion, $1.2 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Bn |
| Mar 31, 2026 | 1.20 Bn |
| Dec 31, 2025 | 1.22 Bn |
| Sep 30, 2025 | 1.22 Bn |
| Jun 30, 2025 | 1.23 Bn |
| Mar 31, 2025 | 1.23 Bn |
| Dec 31, 2024 | 1.25 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.25 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Sep 30, 2023 | 1.25 Bn |
| Jun 30, 2023 | 1.25 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.25 Bn |
| Sep 30, 2022 | 1.25 Bn |
| Jun 30, 2022 | 1.25 Bn |
| Mar 31, 2022 | 1.25 Bn |
| Dec 31, 2021 | 1.25 Bn |
| Sep 30, 2021 | 1.25 Bn |